title: Positive Direct Immunofluorescence Is of Better Value than ELISA-BP180 and ELISA-BP230 Values for the Prediction of Relapse after Treatment Cessation in Bullous Pemphigoid: A Retrospective Study of 97 Patients.
abstract: BACKGROUND
  ELISA-BP180 values and direct immunofluorescence (DIF) are prognostic factors for relapse after treatment cessation in bullous pemphigoid (BP).
  
  
  OBJECTIVE
  To determine the relevance of ELISA-BP230 antibodies for predicting relapse 6 months after treatment cessation.
  
  
  METHODS
  We retrospectively selected patients with BP and available data from ELISA-BP180 and -BP230 and DIF performed at treatment cessation. The rate of relapse was calculated at 6 months. We compared ELISA-BP180 and -BP230 values and DIF in patients with relapse and remission.
  
  
  RESULTS
  We included 97 patients. At 6 months, 25.6% of patients showed relapse. The proportion of patients with an ELISA-BP230 value ≥27 UA/ml was higher, but not significantly, for those with relapse than for those with remission (p = 0.11). The frequency of positive DIF findings was significantly higher for patients with relapse (p = 0.005).
  
  
  CONCLUSIONS
  DIF is of better value than ELISA-BP180 and -230 tests to predict relapse after treatment cessation in BP.
authors: Department of Dermatology, Henri Mondor Hospital, Créteil; France.
authors: Saskia
authors: S
authors: Ingen-Housz-Oro
authors: Julie
authors: J
authors: Plée
authors: Thibaut
authors: T
authors: Belmondo
authors: Michaël
authors: M
authors: Maizières
authors: Bach-Nga
authors: BN
authors: Pham
authors: Sophie
authors: S
authors: Hüe
authors: Nicolas
authors: N
authors: Ortonne
authors: Anne
authors: A
authors: Durlach
authors: Pierre
authors: P
authors: Wolkenstein
authors: Olivier
authors: O
authors: Chosidow
authors: Philippe
authors: P
authors: Bernard
mesh_terms: D000279:Administration, Cutaneous; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001323:Autoantibodies / Q000097:blood*; D001324:Autoantigens / Q000276:immunology*; D002352:Carrier Proteins / Q000276:immunology*; D003598:Cytoskeletal Proteins / Q000276:immunology*; D000071821:Dystonin; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D019085:Fluorescent Antibody Technique, Direct; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000276:immunology*; D024041:Non-Fibrillar Collagens / Q000276:immunology*; D010391:Pemphigoid, Bullous / Q000097:blood* / Q000188:drug therapy*; D011237:Predictive Value of Tests; D012008:Recurrence; D012189:Retrospective Studies; D000097805:Collagen Type XVII
chemical_list: D000305:Adrenal Cortex Hormones; D001323:Autoantibodies; D001324:Autoantigens; D002352:Carrier Proteins; D003598:Cytoskeletal Proteins; D000071821:Dystonin; D007166:Immunosuppressive Agents; D009419:Nerve Tissue Proteins; D024041:Non-Fibrillar Collagens; D000097805:Collagen Type XVII; C486268:DST protein, human